Treatment resistance in inclusion body myositis: the role of mast cells

https://www.sciencedirect.com/science/article/abs/pii/S0960896624000981

Neuromuscular Disorders, Available online 3 May 2024

I Acosta, M Hofer, D Hilton-Jones, W Squier, S Brady

Highlights

• Several inflammatory pathways have been described in IBM.

• Our results show there was a greater number of mast cells present in IBM and neurogenic myositis than in normal muscle and steroid-responsive inflammatory myopathy.

• Neurogenic inflammation may play a role in the pathogenesis of IBM and neurogenic myositis, and this could explain in part the lack of response to immunosuppressive treatment of IBM.

Abstract

Inclusion body myositis is the commonest acquired myopathy in those over 50 years of age. Although it is classified as an idiopathic inflammatory myopathy and the most frequent finding on muscle biopsy in inclusion body myositis is an endomysial inflammatory infiltrate, it is clinically distinct from other myositis, including a lack of response to immunosuppressive medication. Neurogenic changes are commonly reported in inclusion body myositis and inflammatory changes are observed in muscle following neurogenic injury. The objective of our study was to explore whether neurogenic inflammation plays a role in the pathogenesis of inclusion body myositis, possibly explaining its resistance to immunosuppression. The number of mast cells and presence of neuropeptides, substance P and calcitonin gene-related peptide, were assessed in 48 cases of inclusion body myositis, 11 cases of steroid responsive myositis, two cases of focal myositis associated with neurogenic injury, and ten normal controls. The number of mast cells in inclusion body myositis focal and myositis associated to neurogenic injury were significantly greater than that observed in steroid responsive myositis. Our findings suggest that neurogenic inflammation mediated through mast cells may play a role in the pathogenesis of inclusion body myositis, and focal myositis associated to neurogenic injury, and thus, explain in some part its lack of response to immunosuppressive treatments.